Myelodysplastic syndromes (MDS) in young adults are uncommon and underrepresented in transplant cohorts. We evaluated 697 patients aged 18-40 years who underwent first allogeneic hematopoietic cell transplantation (allo-HCT) reported to the EBMT between 2016 and 2021. The primary endpoint was overall survival (OS); sec...
A. J. Jimenez Jimenez, D. Eikema, L. Koster et al.· Bone Marrow Transplantation· 1 citation
Background: Upfront allogeneic stem cell transplantation (allo-SCT) without pretransplant cytoreduction is an established concept in patients with myelodysplastic syndromes with increased blasts (MDS-IB), but the optimal conditioning strategy remains to be defined. While fludarabine and treosulfan (Flu/Treo) has become...
Judith Metzdorf, Artur Schneider, Jacob Pyka et al.· Cancers· 0 citations
It is indicated that PTCy is a safe and effective alternative to ATG in older allo‑HCT recipients, especially in MUD transplants and in MSD recipients aged >65 years, but the findings should be interpreted cautiously given their observational nature and patient heterogeneity.
L. K. Gjærde, C. Peczynski, W. Boreland et al.· Bone Marrow Transplantation· 0 citations
Relapse and non-relapse mortality after transplantation for myelofibrosis are governed by distinct dimensions, and estimating both outcomes independently with genetic and clinical information, in addition to overall survival, establishes an individualized basis for transplant decision-making.
N. Gagelmann, R. Salit, T. Schroeder et al.· Transplantation and Cellular...· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.